Posted on

FDA Panel Endorses Eli Lilly’s Experimental Alzheimer’s Drug Donanemab

Eli Lilly Corporate Center

the staff of the Ridgewood blog

Ridgewood NJ, in a significant development, outside advisers to the U.S. Food and Drug Administration (FDA) unanimously endorsed the efficacy of Eli Lilly’s experimental Alzheimer’s drug, donanemab, for patients with early Alzheimer’s disease. This vote precedes the FDA’s impending decision on the drug’s approval. The panel’s discussion highlighted some unique aspects of Lilly’s trial, which differed notably from the trial design of Eisai and Biogen’s Leqembi, another Alzheimer’s drug that recently gained U.S. approval following a similar advisory committee review.

Continue reading FDA Panel Endorses Eli Lilly’s Experimental Alzheimer’s Drug Donanemab

Posted on

Five Subtypes of Alzheimer’s ID’ed

mfs9se8yhxlwd8xqh5vc 3017149813

the staff of the Ridgewood blog

Ridgewood NJ, an international team of neuroscientists has identified five distinct subtypes of Alzheimer’s disease.Disease subtyping is a method for clustering people into subgroups using medical, epigenomic, transcriptomic, and genomic data.

Continue reading Five Subtypes of Alzheimer’s ID’ed

Posted on

Scientists develop blood test for Alzheimer’s disease

75 1611213456

the staff of the Ridgewood Blog

Ridgewood NJ, scientists have developed a blood test to diagnose Alzheimer’s disease without the need for brain imaging or a lumbar puncture. The antibody-based blood test could enable faster diagnosis of the disease and faster initiation of therapy. It detects a particular form of protein that is specifically related to Alzheimer’s disease. The test still needs to be validated with a broader range of patients.

Continue reading Scientists develop blood test for Alzheimer’s disease

Posted on

FDA Gives Cognito Therapeutics Breakthrough Status on it’s Alzheimer Headset

th 2200758764

the staff of the Ridgewood blog

Ridgewood NJ, Cognito Therapeutics Inc. will soon be conducting late-stage trials of a device for treating Alzheimer’s disease. The trial will involve around 500 US participants wearing a headset for an hour a day over a year. The headset delivers light and sound at a frequency that improves cognitive ability. If Cognito’s headset proves effective, it could see wide adoption in 2024.

Continue reading FDA Gives Cognito Therapeutics Breakthrough Status on it’s Alzheimer Headset

Posted on

Researchers have discovered two novel genes that increase an individual’s risk of developing Alzheimer’s disease

75 1611213456

the staff of the Ridgewood blog

Ridgewood NJ, researchers have discovered two novel genes that increase an individual’s risk of developing Alzheimer’s disease. The researchers used a technique called exome sequencing to identify the genes. Exome sequencing is able to identify rare mutations. The discovery brings scientists closer to finding treatment options and preventative measures for the disease.

  20% off all web services with Spark Driven https://1.sparkdriven.com/aff.php?aff=3  

Posted on

FDA Approves Aducanumab the first new treatment for Alzheimer’s disease in nearly 20 years

external content.duckduckgo 11

the staff of the Ridgewood blog

Ridgewood NJ, Aducanumab is the first new treatment for Alzheimer’s disease that has been approved for use in the US in nearly 20 years. It targets the underlying cause of the disease rather than its symptoms. While it is not a miracle drug, its approval will be a huge boost to dementia research. Alzheimer’s disease affects more than 30 million people around the world, most over the age of 65.

Continue reading FDA Approves Aducanumab the first new treatment for Alzheimer’s disease in nearly 20 years

Posted on

The Effects of CBD on Your Overall Well-Being

cbd oil on amazon theres no such thing

Studies have shown that CBD has its benefits and side effects, and recently, more people have discovered the importance of taking natural medications instead of synthetic drugs. Those who take CBD products tend to experience different effects considering that the results vary between people. By analyzing CBD products’ widespread impact on people, one can determine how it would react to their body. However, it’s essential to note that a lot of stigmatization has surrounded the use of cannabis products in recent years; thus, more studies have been done to determine the effects of CBD. Here are some impacts that CBD would have on your overall well-being. 

Continue reading The Effects of CBD on Your Overall Well-Being

Posted on

Some Hope in the Search for the Cure for Moderate Alzheimer’s Disease

Ridgewood Police Alzheimer's patient was found

file photo by Boyd Loving of RPD searching for a senior suffering from Alzheimer’s

July 7,2018

the staff of the Ridgewood blog

Ridgewood NJ, Alzheimer’s is the most common form of dementia and affects about 50 million people worldwide, according to the Alzheimer’s Association. There is still no cure for the disease or way to stop its progression, although the U.S. Food and Drug Administration has approved some medications to treat symptoms related to memory loss, language and other thought processes.

Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer’s Disease at 18-Months

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (Aβ) levels in the brain measured by amyloid-PET (positron emission tomography). A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant. This study, a Phase II study of 70 patients, is the first study of a BACE inhibitor to show a statistically significant difference in amyloid beta in the brain while also suggesting a delay of clinical symptom decline in exploratory endpoints.

Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease, or mild to moderate dementia due to Alzheimer’s disease with confirmed amyloid pathology by PET screening. Seventy patients were randomized to four treatment arms receiving elenbecestat (5, 15, or 50 mg) or placebo daily. During the study period, more than half the patients in the elenbecestat 5 mg and 15 mg arms were switched to the 50 mg arm for three months or more. The 50 mg treatment arm plus the group switched to the 50 mg arm are hereafter referred to as “50 mg total arm” (38 subjects) with a mean duration of approximately 11 months on 50 mg per day.

Elenbecestat demonstrated acceptable safety and tolerability profile through 18 months of study drug administration. In the elenbecestat 50 mg total arm, the six most common adverse events observed were contact dermatitis, upper respiratory infection, headache, diarrhea, fall, and dermatitis. No serious adverse reactions suggestive of hepatic toxicity were observed in this study.

In addition to the safety objectives, the study assessed Aβ in the brain at 18 months as measured by amyloid PET as well as efficacy in terms of clinical symptoms, which were exploratory objectives in this study.

The elenbecestat 50 mg total arm demonstrated a statistically significant difference in Aβ levels in the brain as measured by amyloid PET compared with placebo (35 subjects participated in this longitudinal amyloid PET assessment). This is the first time in which a significant effect in Aβ in the brain using a BACE inhibitor was confirmed in a clinical study of patients with mild cognitive impairment (MCI) through moderate Alzheimer’s dementia.

CDR-SB (Clinical Dementia Rating Sum of Boxes) was an exploratory endpoint to assess efficacy in terms of clinical symptoms. The study showed numerically less decline in CDR-SB for the elenbecestat 50 mg total arm as compared to placebo of a potentially clinically important difference (41 subjects participated in this assessment), which was not statistically significant. Further, a similar magnitude and direction of differential in decline was observed in a post-hoc analysis of ADCOMS, Eisai’s newly developed assessment scale (Alzheimer’s Disease Composite Score) in the elenbecestat 50 mg total arm as compared to placebo. The study was not powered to show statistical significance compared to placebo on clinical symptoms.

Eisai plans to present detailed results of the study at a future medical meeting.

Elenbecestat, discovered by Eisai, has been jointly developed by Eisai and Biogen since March 2014. The two companies are currently conducting two global Phase III clinical studies (MISSION AD1/2) in early Alzheimer’s disease.

“It is highly encouraging that Study 202 confirmed elenbecestat’s treatment effect in reducing amyloid in the brain and suggested a slowing of clinical decline. Eisai and Biogen will continue to work together to advance the ongoing Phase III program (MISSION AD) in order to contribute a new potential treatment option to Alzheimer’s disease patients as soon as possible,” said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai.

“Biogen is heartened by the safety and tolerability results of this study of elenbecestat,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “We remain committed to research in Alzheimer’s, an area of significant unmet need with a devastating impact on those living with the disease, their families, friends, and society.”

Biogen Safe Harbor
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about results from the Phase II study of elenbecestat, the potential effects of elenbecestat, Biogen’s strategy and plans, and the potential of Biogen’s commercial business and pipeline programs. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data, analysis, or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen’s drug candidates, the occurrence of adverse safety events, we may encounter other unexpected hurdles, which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, or failure to protect intellectual property and other proprietary rights, or uncertainty of success in the development and potential commercialization of elenbecestat.. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.